Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/1817
Full metadata record
DC FieldValueLanguage
dc.contributorLiew, S.en_US
dc.contributorDinh, D.en_US
dc.contributorBrennan, A.en_US
dc.contributorReid, C.en_US
dc.contributorDuffy, S.en_US
dc.contributorOqueli, Ernestoen_US
dc.contributorAjani, A.en_US
dc.contributorClark, D.en_US
dc.contributorFreeman, M.en_US
dc.contributorHiew, C.en_US
dc.contributorJaworski, C.en_US
dc.contributorHutchinson, A.en_US
dc.contributorMok, M.en_US
dc.contributorSebastian, M.en_US
dc.date.accessioned2021-10-12T02:15:04Z-
dc.date.available2021-10-12T02:15:04Z-
dc.date.issued2021-
dc.identifier.govdoc01771en_US
dc.identifier.urihttp://hdl.handle.net/11054/1817-
dc.description.abstractBackground: Drug-eluting stent (DES) design features, including strut thickness, can influence the biological response to percutaneous coronary intervention (PCI). Recent studies suggest the clinical superiority of an ultrathin strut (60 microns), biodegradable-polymer, sirolimus-eluting stent (Orsiro; Biotronik, Berlin, Germany) over a thin-strut (81 microns), permanent-polymer, everolimus-eluting stent (Xience; Abbott, Chicago, IL, USA) in ST elevation myocardial infarction (STEMI) patients undergoing PCI. Objective: We sought to compare the Orsiro stent to current-generation thin-strut, durable-polymer DES in an Australian real-world STEMI population. Methods: Baseline demographics, procedural data, and clinical outcomes for patients undergoing STEMI PCI between 2010 and 2018 from the Melbourne Interventional Group (MIG) registry were evaluated. Long-term mortality (median follow-up 2.2 years) was assessed via linkage with the National Death Index. Results: A total of 4,757 patients were included. The mean age in the Orsiro and thin-strut, durable-polymer DES groups was 64±12.8 and 62.9±12.4 years, respectively (p=0.37). Other clinical and procedural variables were comparable. Conclusion: In a contemporary Australian STEMI PCI cohort, the ultrathin strut, biodegradable-polymer DES was associated with similar 30-day clinical outcomes and long-term mortality as the currently available thin-strut, durable-polymer DES.en_US
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2021-10-07T22:27:53Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2021-10-12T02:15:04Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2021-10-12T02:15:04Z (GMT). No. of bitstreams: 0 Previous issue date: 2021en
dc.titleUltrathin strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, drug-eluting stents for percutaneous coronary revascularisation in the ST-elevation myocardial infarction (STEMI) population.en_US
dc.typeConferenceen_US
dc.type.specifiedPresentationen_US
dc.bibliographicCitation.conferencedateAugust 4-7en_US
dc.bibliographicCitation.conferencename69th CSANZ Annual Scientific Meeting 43rd Annual Scientific Meeting of the International Society for Heart Research ANZET 21en_US
dc.bibliographicCitation.conferenceplaceOnlineen_US
dc.subject.healththesaurusPERCUTANEOUS CORONARY INTERVENTIONen_US
dc.subject.healththesaurusCARDIOLOGYen_US
dc.subject.healththesaurusPCIen_US
dc.subject.healththesaurusSTENTSen_US
dc.subject.healththesaurusSTEMIen_US
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.